MedTrace Logo

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

NCT00734305 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2016-09-01

Study results available
· View outcomes & findings →

Summary

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.

Conditions

Interventions

DRUG

MM-121

Dose escalation Frequency - once weekly

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Crystal Denlinger, MD · Fox Chase Cancer Center

  • Kwok Kin Wong, MD · Dana-Farber Cancer Institute

  • Keedy L Vicki, MD · Vanderbilt University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-05-31
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00734305 on ClinicalTrials.gov